Immunotherapy with low-dose chemoradiation for advanced lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests combining immunotherapy with a shorter course of chemoradiation for locally advanced non-small cell lung cancer that hasn't spread. It aims to see if this approach is more effective and tolerable than standard treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have stage IIB to IIIC non-small cell lung cancer that cannot be removed by surgery.
- Your tumor must show a PD-L1 level of 20% or higher on a tissue test.
- You haven't had prior chemotherapy, radiation, or immunotherapy for advanced lung cancer.
- You are between 18 and 70 years old and able to carry out daily activities (ECOG score 0-1).
- You do not have certain gene mutations (EGFR, ALK, ROS-1) or active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of immunotherapy and chemotherapy before and after standard chemoradiation for patients with stage III lung cancer that cannot be surgically removed. The goal is to see if this approach improves outcomes compared to chemoradiation alone.
This study tests whether adding focused radiation therapy to immunotherapy can help patients with advanced non-small cell lung cancer whose cancer has progressed despite prior immunotherapy. The goal is to see if this combination works better than immunotherapy alone.
This trial tests combining chemotherapy, immunotherapy, and a low dose of radiation before surgery for people with non-small cell lung cancer that is borderline resectable (can potentially be removed but is close to nearby structures). It aims to see if this approach can shrink the tumor enough to allow successful surgery.
This trial tests whether giving low-dose focused radiation and two immunotherapy drugs before lung surgery can improve outcomes for people with operable, resectable non-small cell lung cancer. It aims to shrink or control the cancer before surgery and help reduce the chance it comes back.
This trial tests a combination of radiation therapy before surgery, followed by the immunotherapy drug tislelizumab and the targeted therapy drug anlotinib after surgery, for people with stage II to IIIA non-small cell lung cancer (NSCLC). The goal is to see if this approach can improve outcomes for patients whose tumors can be removed surgically.
This trial tests a new approach for people with stage III lung cancer that cannot be removed with surgery. You would receive immunotherapy (to help your immune system fight cancer) plus chemotherapy first, then standard chemo-radiation, and finally more immunotherapy. The goal is to see if this sequence works better than standard treatment.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.